IP Library Granted Patent US 9,834,800
Granted Patent B2
US 9,834,800 · App. 14/421,220 · Granted Dec 5, 2017

Increased production of terpenes and terpenoids

Inventors: Thomas Oestergaard Tange (Basel, CH); Michael Naesby (Huningue, FR); Christophe Folly (Basel, CH); Fanny Delegrange (Hesingue, FR); Jens Houghton-Larsen (Birkeroed, CH); Simon Carlsen (Copenhagen, DK)
Assignee: Evolva SA
C12P9/00C12N1/16C12N9/1007C12N9/1085C12N9/88C12N15/52C12N15/63C12N15/81C12P5/007C12P5/026C12P7/00C12P7/04C12P15/00C12P17/10C12P23/00C12Y205/01068
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,834,800
App. No.
14/421,220
Granted
Dec 5, 2017
Kind
B2
Abstract

This invention provides recombinant cells and methods for producing terpenes and terpenoids by increasing production or accumulation or both of isoprenoid precursors thereof.

Claims (28)

1. A recombinant host cell for producing a terpene or a terpenoid, wherein the recombinant host cell is genetically engineered to produce reduced expression of an endogenous farnesyl diphosphate (FPP) synthase, an endogenous geranyl diphosphate (GPP) synthase or an endogenous enzyme having both FPP synthase and GPP synthase activity,

wherein reduced expression is produced in the recombinant host cell by:

(a) introducing into the recombinant host cell a heterologous genetic construct encoding the endogenous FPP synthase, the endogenous GPP synthase, or the endogenous enzyme having both FPP synthase and GPP synthase activity operably linked to an exogenous weak promoter, wherein the weak promoter is KEX2, PGK-1, GPD1, ADH1, ADH2, PYK1, Tpi1, PDC1, TEF1, TEF2, FBA1, GAL1-10, CUP1, MET2, MET14, MET25, CYC1, GAL1-S, GAL1-L, CAG, CMV, human UbiC, RSV, EF-1alpha, SV40, MT1, Tet-On, Tet-Off, Mo-MLV-LTR, Mx1, progesterone, RU486 or Rapamycin-inducible promoter;

(b) introducing into the recombinant host cell a heterologous genetic construct encoding the endogenous FPP synthase, the endogenous GPP synthase, or the endogenous enzyme having both FPP synthase and GPP synthase activity operably linked to a messenger RNA destabilizing motif, comprising a M1 motif of SEQ ID NO:28 and/or a M24 motif of SEQ ID NO:29; or

(c) introducing into the recombinant host cell a recombinant genetic construct, the construct comprising a gene encoding the endogenous FPP synthase, the endogenous GPP synthase, or the endogenous enzyme having both FPP synthase and GPP synthase activity operably linked to an endogenous promoter, wherein between the endogenous promoter and the gene encoding the endogenous FPP synthase, the endogenous GPP synthase, or the endogenous enzyme having both FPP synthase and GPP synthase activity is a heterologous insert sequence having the formula:

-X 1 -X 2 -X 3 -X 4 -X 5 -

wherein X 2 comprises at least 4 consecutive nucleotides being complementary to, and forming a hairpin secondary structure element with at least 4 consecutive nucleotides of X 4 ;

wherein X 3 either comprises zero nucleotides or one or more unpaired nucleotides forming a hairpin loop between X 2 and X 4 ;

wherein X 4 comprises at least 4 consecutive nucleotides being complementary to, and forming a hairpin secondary structure element with at least 4 consecutive nucleotides of X 2 ; and

wherein X 1 and X 5 comprise zero, one or more nucleotides;

further comprising one or more recombinant expression constructs encoding heterologous enzymes capable of synthesizing the terpene or the terpenoid comprising two or more isoprene units; and

further comprising a recombinant expression construct encoding a truncated version of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase (HMGR), comprising a catalytically active carboxyl terminal portion thereof, comprising a region from amino acid 619 to amino acid 1025 of SEQ ID NO:8 and having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:8.

2. The recombinant host cell of claim 1 , further comprising a heterologous nucleic acid sequence encoding a dual function enzyme having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:9, wherein the dual function enzyme is an acetoacetyl-CoA thiolase and a HMGR.

3. The recombinant host cell of claim 1 , wherein the recombinant host cell is a eukaryotic cell or a prokaryotic cell.

4. The recombinant host cell of claim 3 , wherein the eukaryotic cell is a mammalian cell, a plant cell, a fungal cell or a yeast cell.

5. The recombinant host cell of claim 4 , wherein the yeast cell is a cell from Saccharomyces cerevisiae, Schizosaccharomyces pombe, Yarrowia lipolytica, Candida glabrata, Ashbya gossypii, Cyberlindnera jadinii, Pichia pastoris, Kluyveromyces lactis, Hansenula polymorpha, Candida boidinii, Arxula adeninivorans, Xanthophyllomyces dendrorhous , or Candida albicans species.

6. The recombinant host cell of claim 5 , wherein the yeast cell is a Saccharomycete.

7. The recombinant host cell of claim 1 , wherein the FPP synthase is yeast ERG20.

8. The recombinant host cell of claim 2 , wherein the HMGR is a truncated HMGR, comprising the catalytically active carboxyl terminal portion thereof and having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO:8.

9. The recombinant host cell of claim 1 , wherein the terpene or the terpenoid is a monoterpene, a diterpene, a sesquiterpene, a triterpenoid or a tetraterpenoid.

10. The recombinant host cell of claim 1 , wherein the terpene or the terpenoid is a molecule comprising an isoprene moiety.

11. The recombinant host cell of claim 9 , wherein the monoterpene is pinenes, myrcene or geraniol.

12. The recombinant host cell of claim 9 , wherein the diterpene is geranylgeranyl pyrophosphate, retinol, retinal, phytol, taxol, forskolin or aphidicolin.

13. The recombinant host cell of claim 9 , wherein the sesquiterpene is amorphadiene, patchoulol, santalol, longifolene or thujopsene.

14. The recombinant host cell of claim 9 , wherein the triterpenoid is squalene.

15. The recombinant host cell of claim 9 , wherein the tetraterpenoid is carotenoid.

16. The recombinant host cell of claim 4 , wherein the yeast cell is a cell from the Saccharomyces cerevisiae species.

17. A method for producing a terpene or terpenoid in the recombinant host cell of claim 1 , comprising culturing the recombinant host cell under conditions wherein the terpene or terpenoid is produced in the recombinant host cell.

Assignments (3)
MERGER Recorded Jun 27, 2024
From: EVOLVA SA
To: DANSTAR FERMENT AG
Reel/Frame 067863/0857 →
CORRECTIVE ASSIGNMENT TO CORRECT THE 5TH ASSIGNOR'S NAME PREVIOUSLY RECORDED AT REEL: 036359 FRAME: 0581. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 17, 2015
From: HOUGHTON-LARSEN, JENS
To: EVOLVA SA
Reel/Frame 036629/0821 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2015
From: OESTERGAARD TANGE, THOMAS; NAESBY, MICHAEL; FOLLY, CHRISTOPHE; DELEGRANGE, FANNY; HOUGHTON, JENS; CARLSEN, SIMON
To: EVOLVA SA
Reel/Frame 036359/0581 →
Continuity (3)
Provisional Application 61684422 · Aug 17, 2012
Provisional Application 61745164 · Dec 21, 2012
Related Publication 20150225754A1 · Aug 13, 2015